Acrivon Therapeutics
ACRV
39 hedge funds and large institutions have $191M invested in Acrivon Therapeutics in 2023 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
733% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 3
117% more funds holding
Funds holding: 18 → 39 (+21)
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
12% more capital invested
Capital invested by funds: $170M → $191M (+$20.7M)
2.22% less ownership
Funds ownership: 71.64% → 69.42% (-2.2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.87M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.95M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.43M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$10.5M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.52M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$545K |
| 4 |
Goldman Sachs
New York
|
-$421K |
| 5 |
Two Sigma Investments
New York
|
-$248K |
ACRV Hedge Fund Activity: Q1 2023 in Review
39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q1 2023, worth a combined $191M — up 12% from $170M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ACRV positions and 3 closed out — a net gain of 22 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $7.96M. The largest seller was Marshall Wace, cutting an estimated $10.5M.
- 39 institutional investors held Acrivon Therapeutics (ACRV) as of Q1 2023, up from 18 in Q4 2022.
- Funds reported $191M of Acrivon Therapeutics stock for Q1 2023, up 12% quarter-over-quarter.
- 25 funds opened new Acrivon Therapeutics positions in Q1 2023 and 3 closed out, a net change of +22 holders.
- The largest Acrivon Therapeutics buyer in Q1 2023 was BlackRock, an estimated $7.96M added.
- The largest Acrivon Therapeutics seller in Q1 2023 was Marshall Wace, an estimated $10.5M sold.
Based on aggregated 13F filings for Q1 2023.